The market turbulence so far in 2016 has many investors rattled, and time will tell if this is the beginning of a deeper downturn. But do pharmaceutical companies Glaxo (LSE: GSK) and Astra (LSE: AZN) offer a place to hide?

One of our top analysts has put together a BRAND-NEW free report for 2016 called A Top Income Share From The Motley Fool, featuring a simple business that's driving forward. To find out its name and why we like it -- for free and without any obligations -- click here now!


Owain Bennallack has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.